
1 Artificial Intelligence (AI) Stock to Buy Before It Jumps 37%, According to a Wall Street Analyst
HSBC has doubled its price target on AMD stock.
The investment bank believes that AMD's new AI chips are powerful enough to help it close the gap with Nvidia.
The potential earnings growth that AMD is expected to clock next year could indeed help it deliver the upside that HSBC analysts are expecting.
10 stocks we like better than Advanced Micro Devices ›
Advanced Micro Devices (NASDAQ: AMD) has underperformed the broader semiconductor sector in the past year. Shares of the chipmaker have slid almost 20% during this period, but it looks like the company's fortunes could turn around in the coming year.
HSBC analyst Frank Lee has doubled his price target on AMD stock to $200, which points toward 37% gains from current levels. Lee says that AMD has managed to close in on Nvidia 's (NASDAQ: NVDA) lead in the artificial intelligence (AI) accelerator market with its latest series of processors, and that could help the former record a big bump in its revenue next year.
Let's take a closer look at the reasons why HSBC has become so bullish on AMD stock, and check if AMD could indeed hit the $200 mark going forward.
AMD's data center revenue could jump significantly thanks to its latest chips
AMD launched its MI350X and MI355X data center graphics processing units (GPUs) last month. The company says that these new processors are three times more powerful than the previous MI300X accelerators, and they even outperform Nvidia's Blackwell GPUs in both AI training and inference workloads.
AMD has equipped these processors with a whopping 288 gigabytes (GB) of high-bandwidth memory (HBM), which is 1.6 times higher than Nvidia's GB200 and B200 AI graphics cards. The serious performance gains and competitiveness that AMD claims to have achieved with its latest GPUs are translating into more business for the company, according to HSBC.
AMD says that it is partnering with multiple AI giants such as Meta Platforms, Microsoft, Oracle, OpenAI, and xAI, among others, to build and deploy AI data centers powered by its processors. In fact, AMD claims that "seven of the 10 largest model builders and AI companies are running production workloads" using its AI accelerators.
This improving adoption of AMD's AI chips can be attributed to a big bump in computing power along with an improvement in energy efficiency, which enables its customers to reduce operating costs. Even better, AMD has reportedly priced its latest AI accelerators competitively so that it can eat into Nvidia's share.
According to HSBC analysts, AMD's MI355 AI GPU is 30% cheaper than Nvidia's B200. Not surprisingly, they are expecting the price-to-performance advantage of AMD's latest chips to translate into healthy data center revenue growth. The company is now expected to achieve $15 billion in AI GPU revenue in 2026, which is higher than the consensus estimate of $9.6 billion on Wall Street.
It's worth noting that AMD ended 2024 with an estimated data center GPU revenue of over $5 billion. So, AMD could potentially triple this business in just two years. Moreover, AMD management is forecasting its data center GPU revenue to reach an annual run rate of "tens of billions of dollars" in the long run, and it looks like its new chips could help it achieve that target.
The projected earnings growth points toward solid upside
Consensus estimates are projecting a 17% increase in AMD's earnings this year, followed by a much stronger jump of 47% in 2026 to $5.71 per share. That won't be surprising, considering the estimated jump of 3x in its data center GPU revenue. AMD has an additional catalyst in the form of the client CPU (central processing unit) market, where it is winning more share, apart from capitalizing on the secular growth of the AI personal computer market.
All this suggests that AMD could indeed hit Wall Street's consensus earnings target in 2026, though there's a chance that it may be able to do better than that. This improved earnings power could translate into more upside on the stock market. AMD is currently trading at 39 times forward earnings, which is a discount to the U.S. technology sector's average of 51.
Even if it trades at a discounted 35 times earnings and achieves $5.71 per share in earnings in 2026, its stock price could hit $200. So, investors can start accumulating this semiconductor stock, as it seems set for a turnaround thanks to its improving stature in AI chips.
Should you invest $1,000 in Advanced Micro Devices right now?
Before you buy stock in Advanced Micro Devices, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Advanced Micro Devices wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!*
Now, it's worth noting Stock Advisor's total average return is 1,072% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Meta Platforms, Microsoft, Nvidia, and Oracle. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
7 minutes ago
- Globe and Mail
Markets Await Consumer Sentiment Reading
Pre-market futures are up again as a very eventful trading week winds to a close. The Dow is currently +0.12%, the S&P 500 is +0.09% and the Nasdaq +0.16% at this hour. The small-cap Russell 2000 is shooting to another orbit this morning, +0.52%. It now leads all major indexes for the past week of trading, as it still tries to catch up with the other indexes year to date. Bond yields have remained fairly steady through a thorough barrage of economic reports Q2 earnings releases, and open speculation about the future tenure of Fed Chair Jerome Powell. The 10-year yield is up a mere 3 basis points (bps) from last Friday, +4.44%. The 2-year continues to shrink gradually, now +3.88%, while the 30-year remains hanging onto its recent 5-handle: +5.00%. Housing Starts & Building Permits Improve, Stay Muted Housing Starts for the month of June remained historically low, coming in slightly ahead of projections to 1.32 million seasonally adjusted, annualized units, up from 1.256 million the prior month, which was the worst performance on new housing starts in five years. Multi-year highs back in April 2022 were 500K higher than they are presently. Building Permits of 1.397 million were also up a bit month over month, from 1.394 million reported for May, which was the weakest level of permits for new homebuilding since June 2020. Back in January of 2022, we were close to 2 million building permits per month — but that was prior to the Fed raising interest rates, which directly sent mortgage rates surging higher. Q2 Earnings Beats for 3M, AmEx & Schwab Minnesota-based industrial conglomerate 3M (MMM) shares are up +3% on the company's beat-and-raise in its Q2 report ahead of today's opening bell. Earnings of $2.16 per share outshone the Zacks consensus of $2.01, for an earnings surprise of +7.46%. Revenues of $6.2 billion in the quarter improved over the $6.12 billion forecast. Earnings guidance for full-year 2025 was also raised to a range of $7.75-8.00 per share. American Express (AXP) also surpassed expectations in its Q2 report this morning, with earnings of $4.08 per share beating the $3.86 expected and the $3.49 per share posted in the year-ago quarter. Revenues of $17.9 billion topped the $17.69 billion estimate, for year-over-year growth of +9%. Shares are flat in today's pre-market, up +6.25% year to date. Financial services major Charles Schwab (SCHW) is having an even better morning, with shares up +5% in the pre-market, adding to its +26% growth year to date, with solid beats on both top and bottom lines in this morning's Q2 report. Earnings of $1.14 per share on revenues of $5.85 billion surged past the $1.09 per share and $5.70 billion, respectively, in the Zacks consensus. What to Expect from the Stock Market Today After today's open, we'll see a preliminary print on Consumer Sentiment for July. This is expected to improve to 61.8 from the prior read of 60.7, which tracks with the present narrative of a healthy environment. Q2 earnings season overall has provided a rosier outlook, and most of the fears of tariffs sandbagging the economy have dissipated. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report 3M Company (MMM): Free Stock Analysis Report American Express Company (AXP): Free Stock Analysis Report The Charles Schwab Corporation (SCHW): Free Stock Analysis Report


Globe and Mail
7 minutes ago
- Globe and Mail
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
Johnson & Johnson JNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion by the end of the decade. Oncology, at present, comprises around 27% of J&J's total revenues. Its oncology sales rose 22.3% on an operational basis in the second quarter to $6.3 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant, plus Lazcluze, contributed significantly to growth as they witnessed strong launches. Though the $50 billion target was well above consensus, J&J seems quite confident in the target, citing strong growth in its marketed cancer drugs and the potential of upcoming launches like TAR-200 in bladder cancer and the subcutaneous formulation of Rybrevant plus Lazcluze for advanced EGFR-mutated non-small cell lung cancer (NSCLC). TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. The subcutaneous formulation of Rybrevant plus Lazcluze has been recommended for approval in the EU while it is under review in the United States. Meanwhile, J&J's oncology pipeline has gained strong momentum in the last year and a half, with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio. If these pipeline drugs are eventually approved, they can also boost JNJ's oncology sales. In the five years from 2019 to 2024, J&J's oncology sales have doubled from $10.7 billion in 2019 to $20.8 billion in 2024. To achieve the $50 billion target in the next 5-6 years, the company needs to more than double its sales from 2024 levels. Though quite optimistic, the target is not unachievable. Competition in the Oncology Space Other large players in the oncology space are Pfizer PFE, AstraZeneca AZN, Merck MRK and Bristol-Myers. Pfizer boasts a strong portfolio of approved cancer medicines like Xtandi, Lorbrena and the Braftovi-Mektovi combination. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. For AstraZeneca, oncology sales now comprise around 41% of total revenues. AstraZeneca's strong oncology sales growth is being driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. Merck's key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Bristol-Myers' key cancer drug is PD-LI1inhibitor, Opdivo, which accounts for around 20% of its total revenues. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 14.6% in the year-to-date period compared with an increase of 1.5% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.97 forward earnings, slightly lower than 15.04 for the industry. The stock is also trading below its five-year mean of 15.70. The Zacks Consensus Estimate for 2025 earnings has risen from $10.60 per share to $10.66 over the past 30 days, while that for 2026 has risen from $10.98 to $11.13 over the same timeframe. J&J has a Zacks Rank #2 (Buy) currently. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report


Globe and Mail
7 minutes ago
- Globe and Mail
Buy, Sell or Hold Alphabet Stock? Key Tips Ahead of Q2 Earnings
Alphabet GOOGL is set to report second-quarter 2025 results on July 23. For second-quarter 2025, the Zacks Consensus Estimate for earnings is pegged at $2.13 per share, up by a penny over the past 30 days and indicates 12.7% year-over-year growth. The consensus mark for second-quarter revenues is pegged at $79.22 billion, indicating growth of 11.02% from the year-ago quarter's reported figure. Alphabet has an impressive earnings surprise history. GOOGL's earnings outpaced the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 14.64%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Alphabet Inc. Price and EPS Surprise Alphabet Inc. price-eps-surprise | Alphabet Inc. Quote Let's see how things have shaped up for the upcoming announcement: Growing AI Usage in Search to Aid GOOGL's Q2 Results Alphabet's to-be-reported quarterly results are expected to benefit from solid momentum in Search and Cloud businesses. The integration of Generative AI (Gen AI) technology into the search engine has been benefiting Google Search. AI-powered Circle to Search is now available on more than 300 million Android devices, with people using it to shop, translate text, and learn more about the world around them. Circle to Search is driving additional Search and is gaining popularity among younger users. The addition of AI mode expands AI Overview's advanced reasoning, thinking and multimodal capabilities. The Zacks Consensus Estimate for second-quarter 2025 Search and other revenues is pegged at $52.36 billion, indicating 8% growth over the figure reported in the year-ago quarter. GOOGL Cloud Gaining Market Share Alphabet has been rapidly growing in the booming cloud computing market. Google Cloud has solidified its position as the third-largest provider in the highly competitive cloud infrastructure market against Amazon 's AMZN cloud arm, Amazon Web Services (AWS), and Microsoft' s MSFT Azure. The solid adoption of the Google Cloud Platform and Google Workspace is expected to have driven growth in the Google Cloud segment. According to Synergy Research Group data, Google Cloud, along with Microsoft, is gaining market share, while AWS continues to lead with a 29% market share in the first quarter of 2025. Alphabet and Microsoft had 22% and 12% market share, respectively. The consensus mark for second-quarter 2025 Google Cloud revenues is pegged at $13.04 billion, indicating 26% growth over the figure reported in the year-ago quarter. However, GOOGL is suffering from a lack of capacity, and until new capacity comes online in 2025, cloud revenues are expected to see increased variability. This is expected to have hurt Alphabet's Google Cloud revenues in the to-be-reported quarter. GOOGL Shares Lag Sector, Industry Image Source: Zacks Investment Research Alphabet's shares have declined 3.1% year to date, underperforming the Zacks Internet Services industry and the Zacks Computer & Technology sector. Over the same timeframe, the sector has returned 9.5% while the industry has dropped 0.9%. GOOGL Stock's Performance GOOGL shares are overvalued, as suggested by Value Score C. Currently, GOOGL is trading at a premium, with a forward 12-month Price/Sales of 6.43X compared with the industry's 5.49X. Price/Sales Ratio (F12M) Technically, GOOGL shares are displaying a bullish trend as they trade above the 50-day and 200-day moving averages. GOOGL Trades Above 50-day & 200-day SMAs Cloud Growth to Drive GOOGL Prospects Alphabet is benefiting from an expanding clientele and rich partner base. Google Cloud is benefiting from its partnership with NVIDIA NVDA. Google Cloud was the first cloud provider to offer NVIDIA's B200 and GB200 Blackwell GPUs and will be offering its next-generation Vera Rubin GPUs. Google Cloud is becoming a preferred choice for enterprises planning to deploy AI agents thanks to the Agent Development Kit and a low-code tool offering Agent Designer. The addition of Wiz to Google Cloud will boost competitive prowess against the likes of Amazon and Microsoft in the cloud computing space. Google Cloud's expanding clientele is expected to boost Alphabet's top line. Google Cloud is now expanding its footprint based on the latest deals with Ecobank in Africa and BBVA. BBVA's deal with Google Cloud will enable Alphabet to deploy Google Workspace with Gemini across the global operations of the bank. Meanwhile, the Ecobank collaboration aims at transforming financial services with advanced analytics and AI and driving digital empowerment across Africa. This offers a significant growth opportunity for Google Cloud in one of the most underpenetrated regions of the globe. GOOGL Stock: Buy, Sell or Hold Ahead of Q2? Alphabet's growing Gen AI capabilities present a potential catalyst for future growth. Its dominant position in the Search market is a strong growth driver. However, a stretched valuation, stiff competition in the cloud space and growing regulatory headwinds make GOOGL shares risky for investors ahead of second-quarter 2025 results. Alphabet currently has a Zacks Rank #3 (Hold), suggesting that it may be wise to wait for a more favorable entry point in the stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report